Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 18, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 330,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,496.5 pence per share; lowest price paid was 1,475.5 pence per share.
- Treasury Holdings (Settled): 496,761,327 shares, representing 9.19% of total issued share capital.
- Treasury Holdings (Including Unsettled): 497,621,327 shares, representing 10.14% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,907,749,188 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 330,000 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share repurchases under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares held in Treasury (496,761,327 settled) against the Company's latest annual report.
- Confirm the percentage of total voting rights held in Treasury (10.14% including unsettled shares) for disclosure threshold calculations.
- Note that the 4,907,749,188 shares in issue (excluding treasury) serve as the denominator for shareholder notification requirements.